Reported 8 months ago
Taipei, June 24, 2024 - Heartfelt Magnesium (6934) has been listed on the emerging stock market, focusing on the medical device sector. Chairman Zheng Jiesheng revealed plans to develop antibiotics for treating rare diseases like fibrocystic cysts with expired patents, and expand into the CDMO field. With around 300 million people worldwide suffering from respiratory diseases, the company aims to tap into the $66.5 billion global market for respiratory inhalers by 2031, emphasizing on portable, competitive inhalers. Heartfelt Magnesium's products cater to asthma and COPD patients, with the Pulmogine series even being FDA approved for use. They are also collaborating with Zambon, an Italian pharmaceutical company, to launch a new antibiotic nebulizer medication for NCFB patients in the US by 2027-2028. The company is actively developing drug-device combination products for treating rare diseases and aims to launch them by 2027.
Source: YAHOO